Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000516221 | SCV000615502 | likely benign | not provided | 2019-03-04 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003362810 | SCV004065030 | uncertain significance | Inborn genetic diseases | 2023-08-02 | criteria provided, single submitter | clinical testing | The c.964G>A (p.E322K) alteration is located in exon 9 (coding exon 8) of the SPTBN2 gene. This alteration results from a G to A substitution at nucleotide position 964, causing the glutamic acid (E) at amino acid position 322 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |